PK/TK Analysis in Stroke Drug Discovery and Development

Pharmacokinetic (PK) and toxicokinetics (TK) can be used as biomarkers of drug exposure as well as markers of efficacy and safety. Understanding the PK and TK of compounds is an important part of stroke drug discovery. Retooling PK and TK studies early in the discovery phase helps in selecting the best drug candidate of stroke.

Custom PK/TK Analysis Services

Ace Therapeutics has the experience, resources, and flexible service options to provide reliable preclinical PK and TK analysis in the early stages of stroke drug development. We can design and conduct PK and TK studies in most species. Experimental design and selection of animal models of stroke can be customized to meet client requirements.

• Samples: Brain tissues
• Assay methods：Radio assay, LC-MS/MS, HPLC, CE or immunochemistry

Our team will work together to provide proactive insight and interpretation of all your PK/TK data. We aim to help our clients select effective and safe drug to accelerate stroke drug discovery and development.

• Single intravenous or oral administration study of the substance
• Brain permeability studies
• Different modes of administration studies
• Different dosage studies
• Different dosing frequency studies
• Different dosage forms and salts
• Tissue distribution and metabolism studies
• Maximum tolerated dose study
• Dose climbing and 7-day repeat dose studies
• Examination of dose-effect relationship
• Drug-drug interactions
• Blood-brain barrier PK
• Toxicokinetics

PK/TK Reporting Parameters

We offer the following PK/TK reporting parameters, which can be fully customized to meet your requirements.

• Maximum plasma concentration (C_max)
• Time to maximum concentration (T_max)
• Area under the plasma concentration versus time curve, AUC (0-t)
• Area under the plasma concentration versus time curve, extrapolated to infinity (AUC(0-∞))
• Apparent terminal half-life (t1/2)
• Mean residence time (MRT)
• Clearance (Cl)
• Volume of distribution (Vd)
• Urinary drug excretion (Ae)
• Renal clearance (Clr)
• Cumulative index
• Dose ratio
• Bioavailability

Applications of Our Services

• Rapid in vivo screening and sequencing of compounds
• Exposure-based proof-of-concept (POC)
• PK/PD correlation
• Complete characterization of compounds for ADME in vivo
• Supporting safe species selection
• Providing a basis for subsequent in vivo safety dose prediction in humans

Ace Therapeutics provides comprehensive in vivo PK/TK analysis services for stroke drug discovery and development. We can develop a PK/TK screening strategy based on the characteristics of different projects, including data interpretation and application, to maximize customer satisfaction. If you are interested in our services, please do not hesitate to contact us!